Pharmaceuticals
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
9610
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC...
2026-01-08 00:00
6800
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update inChina for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final a...
2026-01-07 10:50
8807
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...
2026-01-07 10:44
12445
VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...
2026-01-07 00:00
664
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...
2026-01-06 22:30
2663
Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* - SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ ...
2026-01-06 21:29
7207
Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO:Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to supp...
2026-01-06 21:00
577
Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain
* Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. * QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hou...
2026-01-05 23:00
10168
Earendil Labs Announces Strategic Collaboration with Sanofi to Discover Bispecific Antibodies for Autoimmune Diseases
WILMINGTON, Del., Jan. 5, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disea...
2026-01-05 18:00
8441
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the onl...
2026-01-05 14:00
10216
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility ac...
2026-01-05 11:57
8964
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development. * Under t...
2026-01-05 08:30
8981
ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
* Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. * Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry. SEOUL, South Korea, Jan. 1, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage ...
2026-01-01 14:00
7443
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scar...
2025-12-30 22:00
7294
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public ...
2025-12-30 17:00
14759
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
SHENZHEN, China, Dec. 29, 2025 /PRNewswire/ -- On December 5, 2025, Dr. Lu
Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has
been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025
awards.
2025-12-30 08:45
5734
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...
2025-12-29 14:13
5669
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. ...
2025-12-29 10:24
4914
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a l...
2025-12-29 09:58
4932
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24